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Some academic economists disagree, however, arguing
that prospective economic modelling is better than infor-
mal opinion.
CONCLUSIONS: This study raises doubts about whether
pharmacoeconomics has yet had much impact on R&D
prioritization. If pharmacoeconomics is to succeed in guid-
ing firms towards developing cost effective new products
(i.e., ones delivering greater population health gains per
unit of cost than existing products), then firms may need
stronger incentives to use prospective cost-effectiveness
modeling in R&D decisions.
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OBJECTIVES: To compare the costs of baseline standard
treatment course for iron deficiency anemia with differ-
ent Fe-content medicines.
METHODS: The model for non-complicated iron defi-
ciency anemia treatment was worked out by experts in
the field of hematology: a course of 200 mg Fe daily
for 28 days. There were 5 Fe-content medicines avail-
able in Moscow pharmacies conventionally named H, S,
T, F, G with the same suggested clinical effectiveness. Ac-
tive Fe amount per tablet, necessary mean dose of
drug, mean duration of course treatment, drug price were
taken into account. Data on medicine prices was calcu-
lated as a mean value according to price-lists of Moscow
pharmacies derived from the Internet on April, 20, 1999.
RESULTS: The table below shows the results of this cost-
minimization analysis.
CONCLUSION: The course of treatment for iron defi-
ciency anemia with F-drug that is the cheapest really is
the most expensive. Cost-saving courses are those with S
and G-drugs. Although it is traditionally used in Russia,
price per pack shouldn’t be an economical criteria for
choice of treatment.
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OBJECTIVES: To examine patients’ attitudes to and expe-
riences of NSAIDs, Rubifaciants and oral pain remedies.
METHODS: Subjects were recruited in one of 30 phar-
macies in Scotland representing rural, semi-rural and ur-
ban environments. Subjects who had purchased an Over
the Counter medicine from one of three Topical NSAIDs,
three Rubifaciants or one of four oral pain remedies were
asked to participate in a questionnaire based study. The
questionnaire examined pain assessment pre and post
treatment, side effects experienced, patients’ expectations
of treatment, treatment outcomes, opinion about the rel-
ative merits of the three groups of medicines and demo-
graphic data about the purchaser. The questionnaires
were anonymous but identified the study pharmacy. In-
formation about the effectiveness of different rates of re-
cruitment was also obtained. After an initial emphasis on
pharmacist inducements, the study pharmacist was sta-
tioned in the pharmacies and achieved a high rate of re-
cruitment and returned questionnaires.
RESULTS: Of 430 questionnaires distributed, 302
(70.23%) were returned; 13 patients were excluded due to
spoiled questionnaires. Of the remaining 289 patients, 94
(32.5%) purchased Topical NSAIDs, 105 (36.6%) Rubifa-
ciants and 90 (31.1%) purchased oral remedies. There was
no significant difference between the three groups in pain
scores pre and post treatment (p  0.22). There was a dif-
ference in choice of treatment type by age (p  0.021) with
patients aged over 60 more likely to choose a Topical
NSAID. Those who suffered symptoms less than once a
week and those choosing a Topical NSAID were more
likely to be first time users of the study treatment (both p 
0.001). Those in the Topical NSAID group were also more
likely to report that they would definitely buy the product
again than those in the other treatment groups (p  0.014).
CONCLUSIONS: Initial findings demonstrate a very low
level of adverse events and a high rate of satisfaction par-
ticularly with Topical NSAIDs as represented by a greater
willingness to buy again.
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Indicators
Conventionally named drugs
H S T F G
Fe mg/tab 10 100 80 45 100
Equivalent daily dose
(200 mg daily) tab 20 2 3 5 2
Price per pack USD* 2.06 3.18 4.42 0.95 1.53
Tablet number per pack 100 50 30 10 30
Price per tablet USD 0.02 0.06 0.15 0.01 0.05
Cost per course of 
treatment (28 days) 11.5 3.56 12.38 13.3 2.86
USD 4
*Prices in rubles were converted into USD according to the Central Bank rate
on April 20, 1999
